Zai Lab (ZLAB) CLO Edmondson Frazor Titus III Buys 14,600 Shares
Chief Legal Officer Edmondson Frazor Titus III recently handled 14,600 shares of Zai Lab Limited, adding to a busy stretch of executive moves.
Reviewed by automated data checks against the source filing. How we make and check alerts
Edmondson Frazor Titus III, Chief Legal Officer at Zai Lab Limited ($ZLAB), bought 14,600 shares on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ZLAB is up 3.2% after 1 week, up 0.7% after 1 month and up 25.2% to date (from the $18.52 close on Jun 25, 2026).
ZLAB
Zai Lab Limited
Key Points
- Chief Legal Officer Edmondson Frazor Titus III handled 14,600 shares of Zai Lab Limited on June 25, 2026.
- The biopharmaceutical stock trades around $18.41, moving between a 52-week low of $15.96 and a high of $34.72.
- Citigroup maintains a buy rating on the healthcare company with a price target of $45.00.
Get $ZLAB trade alerts by text
We text you when insiders, Congress or big funds trade $ZLAB. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Zai Lab Limited alert may contain errors. Disclosures
Executive Activity at Zai Lab Limited
Zai Lab Limited saw fresh insider activity when Chief Legal Officer Edmondson Frazor Titus III handled 14,600 shares on June 25, 2026. This transaction follows earlier executive moves at the biopharmaceutical firm, building on a stretch of reported insider filings that also included a trade by William Lis involving 7,040 shares valued at $127,353.60 on June 22, 2026, carried out under a planned arrangement.
Where Zai Lab Limited Stock Stands
Shares of Zai Lab Limited trade near $18.41 on the Nasdaq Global Market. The equity moves within a 52-week range defined by a low of $15.96 and a high of $34.72. Market participants keep an eye on these price levels alongside moving averages and broader sector trends as the healthcare firm navigates its fiscal year.
Analysts Set New Price Targets
Research firms continue to evaluate the biopharmaceutical company's pipeline and commercial products across oncology, immunology, and neuroscience. On August 7, 2026, Citigroup maintained its buy rating on the stock while raising its price target from $44.00 to $45.00. Across the broader analyst community, the company holds a consensus target mean price of $33.14, with a high target of $50.00 and a low target of $24.25 based on 12 analyst opinions.
Inside Zai Lab Limited Operations
Zai Lab Limited is a biopharmaceutical company based in Pudong, China, that focuses on discovering, developing, and commercializing medical products for oncology, immunology, neuroscience, and infectious diseases. Its commercial portfolio includes therapies such as Zejula for ovarian cancer, VYVGART for generalized myasthenia gravis, and various other treatments addressing serious medical needs. The firm partners with major global pharmaceutical entities to expand access to its therapies.
Looking Ahead for Zai Lab Limited
Investors will look toward the company's next earnings report scheduled for November 5, 2026, for updates on revenue growth and operational progress. These periodic disclosures and insider filing updates help market watchers track how executives manage their holdings over time without pointing to any specific investment stance.
Related Filing Alerts
Source: Edmondson Frazor Titus III's Form 4 filing on $ZLAB (Jun 25, 2026). Find the original filing: ZLAB Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts